<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75438">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763944</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00041857</org_study_id>
    <secondary_id>1K24CA160653-01A1</secondary_id>
    <nct_id>NCT01763944</nct_id>
  </id_info>
  <brief_title>Carbohydrate Restriction and Prostate Cancer Growth</brief_title>
  <acronym>CAPS2</acronym>
  <official_title>A Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men With A Rising PSA After Failed Primary Therapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      No treatments have been shown to slow prostate cancer progression after radical
      prostatectomy. We hypothesize that a carbohydrate restricted diet will slow prostate cancer
      growth. A total of 60 men with a rising prostate-specific antigen (PSA) after failed primary
      treatment will be recruited and randomized to either a low-carbohydrate diet (&lt;20 grams
      carbohydrates/day) or a no-diet control (standard of care) for 6 months. The primary outcome
      is PSA doubling time.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PSA doubling time (change in PSA over time)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PSA doubling time will be estimated from PSA measured at baseline, 3 and 6 months post randomization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low carbohydrate, lifestyle counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (&lt;20 grams per day) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control arm will receive no dietary intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.</description>
    <arm_group_label>Low carbohydrate, lifestyle counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received prior radical prostatectomy or definitive local radiation for prostate
             cancer (either external beam radiation, brachytherapy, or combination)

          -  PSA within the past 3 months is between 3 and 10 ng/ml

          -  PSA doubling time (PSADT) &gt;3 months and &lt;24 months

               1. Calculated based at least 2 values in the prior 2 years with the   first  and
                  last PSA separated by at least 3 months

               2. Use all values in the last 2 years to calculate PSADT

               3. PSADT calculated while NOT on hormonal therapy

               4. If prior hormonal therapy use, then documented normal testosterone is required
                  before starting to calculate PSADT

          -  BMI &gt;25 kg/m2

          -  Willing to be randomized to a no-diet control or a low-carbohydrate diet

          -  Reads, writes, and understands English

        Exclusion Criteria:

          -  Anticipate needing secondary prostate cancer therapy within the next 6 months (i.e.
             radiation, or hormonal therapy)

          -  Current use of weight loss medications including herbal weight loss supplements or
             enrolled in a diet/weight loss program

          -  Currently on therapy aimed at altering testosterone levels (includes
             gonadotropin-releasing hormone (GnRH) agonist/antagonist, prior bilateral
             orchiectomy, oral anti-androgens, or 5-alpha reductase inhibitors)

          -  Known distant metastatic disease

          -  Already consuming a carbohydrate-restricted or vegetarian diet

          -  Unable or unwilling to adhere to a carbohydrate-restricted dietary intervention

          -  Weight loss &gt;5% of body weight in the last 6 months

          -  Medical comorbidities that in the opinion of the investigator limits the patient's
             ability to complete this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pao-Hwa Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Smith, RD</last_name>
      <phone>919-660-6719</phone>
      <email>jordan.smith@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Pao-Hwa Lin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 2, 2014</lastchanged_date>
  <firstreceived_date>December 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diet</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>carbohydrate</keyword>
  <keyword>lifestyle</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
